Rationale: 3,4-Methylenedioxymethamphetamine (MDMA, designated as "Ecstasy" if illicitly marketed in tablet form) induces significant decrements in neuronal serotonin (5-HT) markers in humans, nonhuman primates, and rats as a function of dosing and dosing regimen. In rats, MDMA-mediated effects are attributed, in part, to selective high-affinity transport of MDMA into 5-HT neurons by the 5-HT transporter (SERT), followed by extensive 5-HT release. Objectives: To clarify whether SERT-selective effects of MDMA at human monoamine transporters can account for the reported MDMA-induced selective toxicity of serotonin neurons in primate brain. Methods: We investigated the interac- The affinity of MDMA for the human SERT in transfected cells does not clarify the apparent selective toxicity of MDMA for serotonin neurons, although conceivably, its higher efficacy for stimulating 5-HT release may be a distinguishing factor. The findings highlight the need to investigate MDMA effects in DAT-, SERT-, and NET-expressing neurons in the primate brain and the therapeutic potential of NET or DAT inhibitors, in addition to SERT-selective inhibitors, for alleviating the pharmacological effects of MDMA.
Introduction
In the mammalian brain, 3,4-methylenedioxymethamphetamine (MDMA) induces selective decrements in markers of monoamine neurons as a function of dose, dosing regimen, and species (Ricaurte et al. 1988a ). These changes can persist for years after the last exposure (Bowyer et al. 2003; Taffe et al. 2002 Taffe et al. , 2003 Reneman et al. 2002; Hatzidimitriou et al. 1999; Scheffel et al. 1998; Nash and Yamamoto 1992; Slikker et al. 1989) . The most consistent and prominent findings in the primate brain are reductions in brain serotonin (5-HT), its major metabolite 5-hydroxyindoleacetic acid (5-HIAA), the 5-HT transporter (SERT), and tryptophan hydroxylase (Ricaurte et al. 1988a (Ricaurte et al. ,b, 1992 . In humans, the 5-HT system is also most notably affected, with reduced cerebrospinal fluid levels of 5-HT and 5-HIAA and reduced SERT binding potential in the brain (Steele et al. 1994; Buchert et al. 2004; McCann et al. 2005) . These findings are postulated to reflect MDMA-induced neurotoxicity and to account for the neuropsychological effects of prolonged exposure to MDMA (Parrott 2001) . Nevertheless, extrapolation from biochemical markers to neuronal damage or death in humans remains equivocal (Turner and Parrott 2000; Kish 2002; Check 2004) . Although MDMA-induced release of serotonin via the SERT is frequently cited as the significant mechanism in MDMA-induced neurotoxicity, this postulate remains controversial. Other underlying causes have been proposed, including carrier-dependent transport of MDMA, metabolic toxic products, oxidative stress, hyperthermia, apoptosis, and increased extracellular concentrations of dopamine (DA) and 5-HT (Simantov and Tauber 1997; Shankaran et al. 1999; Sanchez et al. 2001; Green et al. 2003) .
The selective effects of MDMA on 5-HT neurons are species-dependent. Serotonin neurons of the primate brain are more susceptible to MDMA-induced changes when compared to rats (Ricaurte and McCann 1992; Slikker et al. 1988 Slikker et al. , 1989 , whereas in mice, MDMA selectively modifies DA neurons while sparing 5-HT neurons (Logan et al. 1988; O'Callaghan and Miller 1994; Xie et al. 2004 ). Dose and dosing regimen are another contributing factor to MDMA-induced neurotoxicity, as high doses of MDMA promotes dopaminergic and noradrenergic neurotoxicity in rats (Commins et al. 1987; Mayerhofer et al. 2001) . However, the susceptibility of catecholamine neurons to MDMA-induced neurotoxicity is unresolved in primates (Turner and Parrott 2000) .
The divergent neurotoxic properties of substituted amphetamines are postulated, among others, to be due to differences in potencies at monoamine transporters (Rudnick and Wall 1992) . The serotonin neuron-selective toxicity of MDMA has been attributed to its higher affinity, uptake, or releasing capacity at the SERT, compared with the dopamine transporter (DAT) or norepinephrine (NE) transporter (NET, Rudnick and Wall 1992) . This view is supported by data derived from the rodent brain, in which MDMA displays a tenfold higher affinity for blocking SERT-mediated 5-HT transport compared with its affinity for the DAT (Steele et al. 1987; Battaglia et al. 1988) . In contrast, amphetamine selectively affects DA neurons, and methamphetamine apparently affects both neuronal subtypes, coinciding with their relative potencies at the three monoamine transporters (see McCann and Ricaurte 2004 for a review).
The conventional hypothesis that MDMA is toxic to serotonin neurons in the human brain because of selective effects at the human SERT has been liberally extrapolated from MDMA inhibition potencies at rodent brain monoamine transporters. Potential species differences, a possible mismatch between inhibition (K i values) and affinity data (K m values), and incomplete evidence that MDMA is a substrate for human monoamine transporters may compromise this extrapolation. To fill this void, we interrogated the influence of MDMA at human monoamine transporters. Foremost, we determined whether the relative potencies of MDMA for inhibiting rodent monoamine transporters extended to human monoamine transporters. Second, we determined directly whether [ 3 H]MDMA is sequestered by cells expressing human monoamine transporters and compared substrate affinities with MDMA potencies for inhibiting human DAT, NET, and SERT. This represents the first direct evidence of DAT-, NET-, and SERT-mediated [ 3 H] MDMA transport into cells and supports the view of MDMA as a substrate based on MDMA-induced ion conductances (Sonders et al. 1997) . To further explore the substrate properties of MDMA, we compared MDMA affinities for inhibiting radiolabeled inhibitor binding to the DAT, NET, and SERT with affinities for blocking monoamine transport, as substrates display relatively weak affinities at radioligand binding sites, whereas transport inhibitor potencies at radiolabeled sites usually correspond to their affinities for blocking the transport of monoamines (Madras et al. 1989a,b; Goulet et al. 2001; Eshleman et al. 1995 Eshleman et al. , 1999 . Our third objective was to monitor the capacity of MDMA to release sequestered monoamines from transporter-expressing cultured cells, as MDMA promotes monoamine release in vivo (except NE) and in vitro (Yamamoto and Spanos 1988; Johnson et al. 1986; Fitzgerald and Reid 1990; Gough et al. 1991; Gudelsky and Nash 1996; Rothman et al. 2001; Zaczek et al. 1990; O'Shea et al. 2001; Mechan et al. 2002; Nash and Brodkin 1991; Koch and Galloway 1997) .
Conceivably, data derived from cell lines expressing the cloned human transporters may not fully reflect transporter pharmacology in human neurons. This is unlikely, as the pharmacological specificities of drugs at biogenic amine transporters expressed in various regions of a macaque monkey's primate brain corresponded closely (r 2 =0.93 for NET, 0.98 for DAT, and 0.99 for SERT) to affinities derived from cell lines expressing cloned macaque monkey transporters .
For the first time, we demonstrate the transport of [ 3 H] MDMA by human monoamine transporters in a stereospecific-, concentration-, time-, and temperature-dependent manner. Contrary to conclusions drawn from rat transporters, MDMA did not display selective effects at the human SERT compared with the DAT or the NET. Indeed, MDMA affinity for the human NET was higher than for DAT or SERT, warranting further investigation of the functional and therapeutic significance of NET-MDMA interactions.
Methods
Stable expression of DAT, NET, and SERT in HEK-293 cells Human embryo kidney (HEK)-293 cells were stably transfected with the human DAT, NET, or SERT as previously described Goulet et al. 2001) . Cells were grown in 145-mm untreated tissue culture dishes (Greiner America, Inc., Lake Mary, FL) in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 100 U ml −1 penicillin, 100 μg streptomycin, and 0.1 mM nonessential amino acids (all from Life Technologies, Rockville, MD), at 5% CO 2 in a 37°C water-jacketed incubator. (Madras et al. 1989b (Madras et al. , 1996 Goulet et al. 2001 ). Experiments were terminated by centrifugation and aspiration of the supernatant as described above. Nonspecific binding, measured with fluoxetine (10 μM, SERT), (−)-cocaine (30 μM, DAT), and desipramine (30 μM, NET) was subtracted from total dpm to calculate specific binding. H]DA) in an uptake buffer at 37°C. After steady-state incubation, cells were exposed to various concentrations of test drugs in an uptake buffer (200 μl). After 15 min, the release reaction was terminated by placing the test tubes in ice. Cells were harvested by centrifugation at 0°C followed by rapid aspiration. Nonspecific binding was determined in the presence of 10 μM of transport uptake inhibitors, which was a 15-min pre-treatment before incubation with radioligands, and subtracted from total counts to yield specific accumulation.
Data analysis
All points were assayed in triplicate, and each experiment was independently repeated at least three times (except where noted) with different cell preparations. Data analyses were performed as previously described Goulet et al. 2001 ) using GraphPad Prism software (San Diego, CA). In uptake experiments, K i values were calculated according to the formula K i =IC 50 /(1+L/K m ) (Cheng and Prusoff 1973) (Fig. 1) . Table 1 porter-dependent. Transport of [ 3 H](±)-MDMA by the DAT, NET, and SERT was rapid and achieved steady state within 10 min (Fig. 2a-c (Fig. 2a ) was higher than corresponding values for NET or SERT (Fig. 2b,c) . Under the present conditions, approximately 67, 52, and 60% of [ 3 H](±)-MDMA transport were DAT-, NET-, or SERT-mediated, and the remainder of [ 3 H](±)-MDMA cell-associated radioactivity was not carrier-mediated. The accumulation of radioactivity in the absence of a transporter is attributable to the conditions of the centrifugation assay, which does not tolerate extensive washing procedures. (Fig. 3a, top (Madras et al. 1989a; Goulet et al. 2001; Eshleman et al. 1999 Another parameter to help clarify the substrate properties of (±)-MDMA at the DAT is to compare its potency for releasing [ 3 H]DA from human (h)DAT cells with MDMA affinity for transport. Initially, we determined the effect of incubation time on drug-induced [ 3 H]DA release, generated dose-response curves with mazindol, DA, and MDMA, and terminated the incubations after 5, 15, or 30 min. With 30-min incubations, even high concentrations of the uptake inhibitor mazindol released no more than 10% of accumulated radioligands. In contrast, DA-and MDMAinduced release was almost identical at all incubation times. Based on these results, release assays were terminated after 15 min. The uptake inhibitor mazindol was inactive in the release assays. In contrast to mazindol, the substrates DA and MDMA were active in both uptake and release assays. Cells were preloaded with [ 3 H]DA and then incubated with (±)-MDMA or DA. (±)-MDMA released DA from the cells, in a concentration-dependent manner, with an apparent affinity (1,290±198 nM) that corresponded to its affinity as a substrate (Fig. 3d and (Table 1 and Fig. 5a, top left) . Unlabeled (±)-MDMA was a relatively weak inhibitor of [ (Table 4 ). The apparent (Fig. 6 ).
Discussion
It is well established that MDMA is selectively neurotoxic to the brain 5-HT neurons in rats, guinea pigs, and primates as a function of dose and dosing regimen. The mechanisms by which MDMA induces neurotoxic effects remain controversial. Carrier-dependent transport of MDMA metabolic toxic products, oxidative stress, hyperthermia, apoptosis, and increased extracellular concentrations of DA and 5-HT are postulated as underlying causes (Simantov and Tauber 1997; Shankaran et al. 1999; Sanchez et al. 2001; Green et al. 2003) . The selective neurotoxic effects of MDMA on serotonin neurons are nonetheless frequently attributed to the relatively higher affinity of MDMA for the rodent SERT compared with the DAT (Rudnick and Wall 1992; Johnson et al. 1991; Steele et al. 1987) . This premise has been extrapolated to the human brain (Colado et al. 2004) in the absence of supportive evidence with human transporters. The present report reexamines whether the relative affinities of MDMA for human monoamine transporters, a conduit of entry of MDMA into monoaminergic neurons, can account for its selective neurotoxic effects of 5-HT neurons in primates.
Based on three independent measures of relative potencies of MDMA at the human monoamine transporters, we now conclude that the selective toxicity of MDMA on 5-HT neurons in the primate brain cannot be attributed to higher MDMA affinity for the SERT compared with the DAT or NET. The only distinctive property displayed by MDMA, with possible implications for the selective neurotoxic effects of MDMA, was its greater capacity to deplete preloaded intracellular [ ]MDMA accumulation by DAT, NET, and SERT was blocked by the potent uptake inhibitors mazindol, desipramine, and fluoxetine (respectively), again reflecting carrier-mediated transport; 7. MDMA affinities at DAT, NET, and SERT radioligand binding sites were lower than their corresponding affinities in transport assays or their affinities to block monoamine transport, findings paralleling those for DA, NE, and 5-HT.
These data imply that the binding domain of MDMA and endogenous monoamine substrates are different from that of inhibitors, a finding highlighted by others (Madras et al. 1989a; Eshleman et al. 1999) .
Contrary to data derived from rat transporters, MDMA displayed higher affinity for the human NET and lower affinities for the SERT and DAT, which were similar. However, the apparently low affinity of [ Mortensen et al. (1999) , in a side-by-side comparison, reported that MDMA potency for blocking the human SERT (IC 50 819 nM) was fourfold lower than corresponding values for the rat SERT (IC 50 196 nM). An overall comparison with rat transporters is instructive, as the affinity of MDMA for inhibiting 5-HT transport into rat synaptosomes was tenfold higher than for rat DAT or NET (Battaglia et al. 1988) . In a reexamination of these values, MDMA affinities for rat transporters confirmed this rank order of potencies (SERT>NET≫DAT), although the differences between SERT and NET were less robust than in later reports (Rothman and Baumann 2003) . The apparent species difference may be attributable to differences in assays conducted with cloned transporters (present study) compared with rat brain synaptosomes, but several reports contradict this postulate (Eshleman et al. 1999) . In HeLa cells transiently expressing the SERT, the potency of MDMA to inhibit [ 3 H]5-HT uptake was similar to reports derived from brain tissue (Mortensen et al. 1999) , and the pharmacological specificities of drugs at biogenic amine transporters expressed in various regions of the macaque monkey primate brain corresponded closely (0.93 NET, 0.98 DAT, and 0.99 SERT) to their affinities derived from cell lines expressing cloned macaque monkey transporters .
The selective effects of MDMA on 5-HT neurons may be attributable to the greater effectiveness of MDMA in releasing a higher proportion of intracellular 5-HT from preloaded SERT-expressing cells compared with DA or NE release from DAT-and NET-expressing cells, respectively. Furthermore, MDMA-induced 5-HT release was more extensive than 5-HT-mediated release, while DA and NE were marginally more effective than MDMA in promoting autorelease. Accordingly, MDMA may trigger distinct biochemical sequelae in neurons expressing the SERT compared with DAT or NET. There are several consequences of enhanced 5-HT release that can potentially underlie the selective neurotoxic effects of MDMA. For example, N-terminal phosphorylation of the DAT is required for release of amphetamine but not for amphetamine transport (Khoshbouei et al. 2004) . If this process generalizes across all three transporters, the robust 5-HT releasing capacity of MDMA at the SERT may reflect a unique capacity of MDMA to promote phosphorylation at the SERT compared with the DAT or NET, enhancing carrier-mediated release. Conceivably, if transport, release, and transporter trafficking induced by MDMA are linked, then MDMA may regulate SERT differently than DAT or NET. The SERT can be internalized (Ramamoorthy et al. 1998 ), but 5-HT inhibits this process and maintains cellsurface expression to permit further accumulation of exogenous (e.g., MDMA) and endogenous substrates (Ramamoorthy and Blakely 1999) . Thus, the magnified MDMA-induced release of 5-HT can lock SERT on the surface, prevent SERT internalization, and enhance intracellular accumulation of MDMA, neurotransmitters, and toxic metabolites, leading to neuron terminal adaptation or toxicity. In contrast to the SERT, DAT internalization is promoted by amphetamine and DA, thereby reducing transport capacity and diminishing DAT cell-surface availability (Saunders et al. 2000; Sandoval et al. 2001; Hansen et al. 2002) . NET is also susceptible to internalization and downregulation, but the effects of NE or MDMA on NET trafficking are not known (Jayanthi et al. 2004 ). Conceivably, MDMA prevents SERT internalization but promotes DAT and NET internalization, either directly or consequent to MDMA-induced 5-HT, DA, and NE release, thereby potentiating further sequestration of MDMA or putative toxic metabolites to enter 5-HT neurons. Our approach provides a simple model system to investigate whether the transport and release of MDMA differs from that of endogenous substrates and whether it triggers regulatory processes unique to each monoamine transporter.
The capacity of MDMA to promote 5-HT, NE, and DA release from slices, synaptosomes, or in vivo is amply documented (Nichols et al. 1982; Johnson et al. 1986; Fitzgerald and Reid 1990; Berger et al. 1992; Rothman et al. 2001; see White et al. 1996; Green et al. 2003 for a review). However, it should be noted that MDMA interactions in vitro will not necessarily be conserved in vivo (Rothman and Baumann 2003) , as other neuronal factors may influence MDMA effects on transporter function. In fact, MDMA-induced monoamine release in vivo can occur through transporter-mediated release, which is presumably the mechanism observed in the present studies, or via exocytotic release (i.e., impulse-dependent). This may be particularly relevant to MDMA-induced DA release, as both impulse-and transporter-mediated release has been reported (Yamamoto et al. 1995) . A carrier-mediated mechanism of MDMA-induced 5-HT release has been amply documented (Gudelsky and Nash 1996; Mechan et al. 2002) , while the contribution of impulse-dependent mechanisms has not been explored.
Interactions of MDMA with multiple transporters, autoreceptors, and/or postsynaptic receptors may also affect in vivo physiology. MDMA-induced release of DA, but not 5-HT, is inhibited by pretreatment with the NET inhibitor, desipramine, or by depleting brain NE (Shankaran and Gudelsky 1998) , which suggests that the MDMA-induced DA increase in vivo may also result from NET transport of MDMA (Shankaran and Gudelsky 1998) . Receptors may also contribute to MDMA effects, as MDMA-induced DA release is markedly attenuated by 5-HT2A receptor blockade (Yamamoto et al. 1995; Gudelsky and Nash 1996) . α2-Adrenergic receptors are also implicated in MDMAinduced 5-HT release (Battaglia et al. 1988) , as MDMA has a relatively high affinity for these receptors, and they are present on 5-HT terminals (Green et al. 2003 ). Finally, a novel candidate receptor, the trace amine receptor1 (TA 1 ), may also mediate some of the pharmacological effects of MDMA (Bunzow et al. 2001 ) by four or more mechanisms. First, MDMA and amphetamine activate TA 1 (Borowsky et al. 2001; Miller et al. 2005) . Second, MDMA potentiates TA 1 activity if cotransfected with the DAT (Miller et al. 2005 ) and, therefore, may influence TA 1 activity by modulating DAT, NET, or SERT. Third, the trace amine phenylethylamine (PEA) is an effective substrate for DAT and NET (Madras et al. 2004 ) and a potent agonist at TA 1 . Conceivably, MDMA blocks PEA transport and promotes PEA release to modulate TA 1 activity. Finally, it has been postulated that the trace amines function as endogenous neuromodulators of classical monoamine neurotransmitters, and MDMA-induced modulation of trace amines may affect monoamines (Berry 2004; Sotnikova et al. 2004) . Our findings clearly demonstrate the capacity of MDMA to release NE via the human NET. MDMA reportedly stimulates NE release in rodent brain preparations, a process blocked by the NET-selective inhibitor desipramine (Steele et al. 1989; Lavelle et al. 1999; Rothman et al. 2001; Fitzgerald and Reid 1993) , but not confirmed by microdialysis in vivo. MDMA reportedly also promotes tachycardia in rats and humans (Gordon et al. 1991; Hayner and McKinney 1986) , desipramine-sensitive vasoconstriction in vitro (Fitzgerald and Reid 1994) , and cardiovascular mortality in humans (Dowling et al. 1987) . Additionally, MDMA has been linked to intracerebral hemorrhage (Harries and De Silva 1992) , with cerebral hyperperfusion demonstrated in rat (Kelly et al. 1994) . All of these effects may be related to the high affinity of MDMA for the NET, capacity of MDMA to release NE, and agonist effects at α2-adrenoceptor receptors (Lavelle et al. 1999) . Notably, high doses of MDMA can deplete DA and NE in rat and guinea pig brains (Commins et al. 1987; Mayerhofer et al. 2001) . Thus, the high affinity of MDMA as a substrate for the human NET warrants further consideration, particularly in devising medications to treat the consequences of acute or repeated exposure to MDMA.
At a practical level, our findings highlight the need to systematically investigate the therapeutic potential of DAT, NET, and SERT inhibitors to alleviate the acute and longterm pharmacological consequences of MDMA. In rodents, a serotonin-selective drug inhibits MDMA-induced effects on the immune system and partly attenuates anxiety and depressive-like behaviors (Pacifici et al. 2004; Thompson et al. 2004) . In human users, the serotonin-selective transport inhibitor citalopram reportedly attenuates the acute psychological (heightened mood, increased self-confidence, and enhanced sensory perception) effects of MDMA (Liechti et al. 2000) . Whether a SERT inhibitor will also curtail MDMA-induced transformation of serotonin neurons in the human brain after repeated use is unknown. Equally intriguing is whether high-affinity NET-selective inhibitors or nonselective monoamine transport inhibitors will be as, or more, effective than SERT inhibitors in diminishing the acute and long-term consequences of MDMA.
